Kodiak matches Regeneron’s Eylea in macular edema phase 3, lighting Beacon of hope after flop

[cafead]

via Kodiak Sciences has bounced back from the failure of its eye disease drug candidate, noting that it has matched Regeneron and Bayer’s blockbuster Eylea in a phase 3 trial of macular edema due to retinal vein occlusion (RVO).

article source